BiologicalDrug
Margetuximab clinical trials
Also written MGAH22 and Margenza.
- studies test it
- 9
- open now
- 0
- in phase 3
- 2
- first study started
- 2010
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 2
MacroGenics (6) · Dana-Farber Cancer Institute (1) · Zai Lab (Shanghai) Co., Ltd. (1) · MedSIR (1)
Often tested with
Tested in the same studies.
Tebotelimab (2) · Trastuzumab (1) · Retifanlimab (1) · Tucatinib (1) · Capecitabine (1)
Studies
Open first, then newest update. How each study uses margetuximab is read from its arms, and is right about nine times in ten.
Testing it · 9
- MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04425018Written as Margetuximab
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedPhase 2/3MacroGenicsNCT04082364Written as margetuximab
- Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerCompletedPhase 1/2MacroGenicsNCT02689284Written as Margetuximab 10 mg/kg
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerCompletedPhase 3MacroGenicsNCT02492711Written as Margetuximab
- Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerCompletedPhase 2MacroGenicsNCT01828021Written as Margetuximab
- Safety Study of MGAH22 in HER2-positive CarcinomasCompletedPhase 1MacroGenicsNCT01148849Written as margetuximab
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedPhase 1MacroGenicsNCT03219268Written as margetuximab
- A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCActive, not recruitingPhase 2Zai Lab (Shanghai) Co., Ltd.NCT04262804Written as Margetuximab
- Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerWithdrawnPhase 2MedSIRNCT05227131Written as Margetuximab
Codes
What other systems call margetuximab · ClinicalTrials.gg INT000659
- MeSH (NLM) C000617981margetuximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K911R84KEWMARGETUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2473851One source FDA
- Wikidata Q109356831MargetuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91733MargetuximabOne source FDA
- DrugBank DB14967One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000617981 | margetuximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K911R84KEW | MARGETUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2473851 | — | One source FDA |
| Wikidata | Q109356831 | Margetuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91733 | Margetuximab | One source FDA |
| DrugBank | DB14967 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.